The T2 Protect AD Study is a national multi-site clinical trial testing an investigational drug for people with mild to moderate Alzheimer’s disease (AD). The trial is designed to determine if the study drug can protect against, or slow down, memory and thinking problems that increase as Alzheimer’s disease progresses.

**T2 Protect AD Basic Eligibility Criteria**

- Women and men aged 50-85
- Diagnosed with mild to moderate Alzheimer’s disease
- Taking Alzheimer’s medication(s) for at least three months:
  - Donepezil/Aricept® or rivastigmine/Exelon® or galantamine/Razadyne®
  - With or without memantine/Namenda®
- Living in the community (not in a residential nursing home)
- Participants must have a study partner who knows the participant well and can come to study visits.
- Willing to participate in the T2 Study for 48 weeks

**What happens during the T2 Protect Study?**

Participation in the study will take 48 weeks. A potential participant will first go through a screening process to see if they are eligible to take part in the clinical trial.

Screening includes:

- Memory and thinking tests
- EKGs (a look at your heart rhythms)
- MRI scans (a picture of your brain that shows changes related to Alzheimer’s disease)

For more information or to volunteer, please contact:

Hardin Stevens  
(859) 323-2997  
Hardin.Stevens@uky.edu

www.T2Protect.org